Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 62% of modeled bridge. Strengths: Bed Count, Commercial Payer %. Risks: Occupancy Rate. Risk-adjusted uplift: $2.1M (vs $3.4M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $1.3M | $1.3M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $1.2M | $35K | $1.3M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $198K | $587K | $785K | $2.5M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $41K | $41K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 68.1% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $323K | $645K | $968K | $1.3M | $1.3M | $1.3M | $1.3M |
| Denial Rate Reduction | $0 | $319K | $639K | $958K | $1.3M | $1.3M | $1.3M | $1.3M |
| A/R Days Reduction | $0 | $262K | $523K | $785K | $785K | $785K | $785K | $785K |
| Clean Claim Rate | $0 | $21K | $41K | $41K | $41K | $41K | $41K | $41K |
| Cumulative | $0 | $924K | $1.8M | $2.8M | $3.4M | $3.4M | $3.4M | $3.4M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $3.4M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 50% / 7.7x | 55% / 8.9x | 59% / 10.1x | 61% / 10.7x | 63% / 11.3x |
| 9.0x | 45% / 6.5x | 50% / 7.5x | 54% / 8.6x | 56% / 9.2x | 58% / 9.7x |
| 10.0x | 41% / 5.5x | 45% / 6.5x | 49% / 7.5x | 51% / 7.9x | 53% / 8.4x |
| 11.0x | 36% / 4.7x | 41% / 5.6x | 45% / 6.5x | 47% / 6.9x | 49% / 7.4x |
| 12.0x | 32% / 4.0x | 37% / 4.8x | 41% / 5.7x | 43% / 6.1x | 45% / 6.5x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 3% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 6.3x, adding 2.1 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $10.1M | — | $10.1M | 15.6% |
| Year 1 | $10.4M | +$2.3M | $12.7M | 19.6% |
| Year 2 | $10.7M | +$3.4M | $14.1M | 21.9% |
| Year 3 | $11.0M | +$3.4M | $14.4M | 22.4% |
| Year 4 | $11.4M | +$3.4M | $14.8M | 22.9% |
| Year 5 | $11.7M | +$3.4M | $15.1M | 23.4% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $645K | $968K | $1.3M | $1.5M |
| Denial Rate Reductio | $639K | $958K | $1.3M | $1.5M |
| A/R Days Reduction | $393K | $589K | $785K | $942K |
| Clean Claim Rate | $21K | $31K | $41K | $50K |
| Total | $1.7M | $2.5M | $3.4M | $4.1M |
Peer Context — Where This Hospital Sits
Key metrics vs 25 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 15.6% | -12.4% | 4.3% | 14.5% | P76 |
| Net-to-Gross | 37.8% | 38.0% | 45.1% | 68.1% | P20 |
| Occupancy | 20.5% | 26.3% | 32.9% | 56.1% | P16 |
| Rev/Bed | $1.7M | $536K | $1.7M | $2.4M | P48 |
| Exp/Bed | $1.4M | $621K | $1.4M | $2.1M | P48 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.